anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. A method of producing a smoking article incorporating a flavourant, wherein an ionic solution and a mixture, said mixture comprising a flavourant and carageenan, are intercontacted thus to effect a sol to gel transformation of the carageenan and thereby provide a stable flavour substance, said stable flavour substance thereafter being incorporated with smoking material and/or an outer wrapper of said smoking article such that said flavourant is released from said stable flavour substance under the influence of heat from the burning coal of said smoking article. 2. A method according to Claim 1, wherein said carageenan is kappa-carageenan. 3. A method according to Claim 1 or 2, wherein said ionic solution is an aqueous ionic solution. 4. A method according to any one of the preceding Claims, wherein said ionic solution provides a source of potassium ions. 5. A method according to Claim 4, wherein said ionic solution is potassium chloride solution. 6. A method according to any one of the preceding Claims, wherein said mixture of flavourant and carageenan is added to said ionic solution. 7. A method according to any one of the preceding Claims, wherein said mixture of flavourant and carageenan is intercontacted with said ionic solution by means of the spraying action of an atomiser. 8. A smoking article incorporating a stable flavour substance, which stable flavour substance comprises a flavourant trapped in carageenan obtainable by the process of Claim 1, and said stable flavour substance being incorporated in smoking material and/or an outer wrapper of said smoking article. 9. A foodstuff product incorporating a stable flavour substance, said stable flavour substance comprising a flavourant trapped in carageenan obtainable by intercontacting an ionic solution and a mixture, said mixture comprising a flavourant and carageenan, thus to effect a sol to gel transformation of said carageenan and thereby provide said stable flavour substance, and said stable flavour substance being such that said flavourant is released from said stable flavour substance upon cooking of said foodstuff product.
A dressing and method of treating wounds is provided. The dressing can comprise water-soluble or swellable polymers which are capable of forming a viscous aqueous or non-aqueous solution and form a gel, particularly a foam form of the gel. The dressing can be constructed in the form of a sponge or sheet impregnated with the gel, or coated onto a non-porous, porous or micro-porous substrate. The dressing can also be provided in a form of a dehydrated powder, such as one which can be sprinkled under a flap of tissue and which will hold the flap down as a substitute for the use of stitches. Wounds treated with dressings in accordance with embodiment of the invention will tend to heal without the formation of a typical hard scab. The gel provides an excellent surface from which to apply tooth whitener to the teeth. The solubility of the material may be adjusted through the addition of non-interacting secondary raw materials to the liquid state formulation mix, or sprayed over the completed product to form a bi-layer, tri-layer, or other multiple layer material that can demonstrate varied solubility and degradation over time when compared to a single formulation mix and subsequent freeze drying or other means of processing to form the desired product.
The present invention relates generally to a molecular marker of the integrity of the extracellular matrix in an animal including a human subject. More particularly, the present invention provides a molecular marker of cartilage integrity. The identification of the molecular marker in circulatory or tissue fluid is indicative of disrepair of the extracellular matrix and in particular cartilage such as caused or facilitated by trauma or a degenerative disease or other condition, for example, arthritis or autoimmunity. The molecular marker is preferably in the form of a glycoprotein but the instant invention extends to genetic sequences encoding the polypeptide portion of the glycoprotein.  Expression analysis of such genetic sequences provides predictive utility in detecting normal or abnormal extracellular matrix development. The identification of the molecular marker of the present invention enables the development of a range of diagnostic and therapeutic agents for degeneration of extracellular matrix or the poor development of the matrix at the fetal and postnatal stages including testing for mutations in the gene sequence in human disease such as but not limited to cartilage disease or arthritis.. In a most preferred embodiment, the molecular marker is referred to herein as "WARP" for von Willebrand Factor A-Related Protein. The corresponding genetic form of WARP is referred to herein as "WARP".
There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). During Part A, B and D, subjects will receive open label mepolizumab (100 mg SC) every 4 weeks and during Part C, subjects will receive placebo SC every 4 weeks.
The recommended dose of THALOMID for an episode of cutaneous ENL is 100 to 300 mg/day once daily orally with water, preferably at bedtime and at least 1 hour after the evening meal. Initiate dosing for patients weighing less than 50 kilograms at the low end of the dose range.

Consider dosing in the higher dosage range for patients with a severe cutaneous ENL reaction, or in those who have previously required higher doses to control the reaction (possibly up to 400 mg/day) once daily at bedtime or in divided doses with water, at least 1 hour after meals.

Consider concomitant use of corticosteroids in patients with moderate to severe neuritis associated with a severe ENL reaction. Steroid usage can be tapered and discontinued when the neuritis has ameliorated.

Continue dosing with THALOMID until signs and symptoms of active reaction have subsided, usually a period of at least 2 weeks. Patients may then be tapered off medication in 50 mg decrements every 2 to 4 weeks.

Patients who have a documented history of requiring prolonged maintenance treatment to prevent the recurrence of cutaneous ENL or who flare during tapering should be maintained on the minimum dose necessary to control the reaction. Tapering off medication should be attempted every 3 to 6 months, in decrements of 50 mg every 2 to 4 weeks.
The invention discloses a full Ma Yuanshan clone antibody capable of neutralizing equine influenza virus and application thereof. The Quan Mayuan monoclonal antibody consists of a light chain and a heavy chain, wherein the amino acid sequence of the light chain is shown as SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown as SEQ ID NO. 2. Cell experiments and animal experiments prove that the full Ma Yuanshan clone antibody has good capability of neutralizing the equine influenza epidemic strain JL 89. Therefore, the full Ma Yuanshan clone antibody has extremely high research value, and can carry out passive immune protection in the early stage of pandemic so as to reduce the harm of viruses during vaccine production. Meanwhile, the invention mainly analyzes the binding epitope of the full Ma Yuanshan clone antibody and HA protein, and provides a foundation for the development of protective influenza vaccine.
The invention provides a burdock wine with a health-care function, and a preparation method thereof. The method comprises the steps that: burdock leaves are washed, bake-dried, and crushed into coarse powder; the coarse powder is sealed by using a cloth bag; the cloth bag is impregnated by using 20-200 time by volume of an impregnation solvent for 5-20 days under normal temperature; the medicine bag is removed; and the impregnation solution is filtered and concentrated to a required concentration, such that the burdock wine is obtained. The impregnation solvent is preferably 30-70 DEG rice wine or sorghum liquor, and more preferably 45 DEG rice wine. The burdock wine provided by the invention has the functions of wind-dispersing, heat-dissipating, lung ventilating, eruption promoting, detoxifying, sore-throat relieving, and the like. The raw materials are easy to obtain, and raw material dosage is low. The cost is low, and effect is substantial.
Participants will receive the intervention, Mindoula plus DANA, which involves working with a case manager via an app for 12 weeks. The case manager will help the participant cope with the stresses of caregiving as well as remind them to use the DANA cognitive assessment app. This arm will also take the study's psychological surveys.
Gallstones in the common bile duct (CBD) may be asymptomatic but may lead to complications such as acute cholangitis or acute pancreatitis. EST is widely used for the treatment of bile duct gallstones. Despite its efficacy and improvements over time, EST is still associated with complications such as hemorrhage, perforation, pancreatitis, and permanent loss of function of the sphincter of Oddi (SO). Permanent loss of SO function can cause duodenobiliary reflux, bacterial colonization of the biliary tract, gallstone recurrence, cholangitis, and liver abscess.

Endoscopic papillary balloon dilation (EPBD) was first proposed in 1983 and it is now recognized as an alternative technique for the removal of CBD gallstones. The small balloon (diameter \<8 mm) is less invasive, reduces the occurrence of adverse effects, and preserves the SO function, but it has limitations in the presence of CBD gallstones ≥10 mm in diameter. EST combined with endoscopic papillary large-balloon dilation (EPLBD) has been introduced for patients with large gallstone, but EPLBD widens the distal common bile duct and still may cause SO function damage, partially or completely. Repairing the ampulla of Vater and SO may reduce the long-term complication rates, especially gallstone recurrence. Unfortunately, no efficient strategy has been proposed. The present pilot study aimed to examine the feasibility and efficiency of an innovative strategy named endoclip papilloplasty to repair the damaged ampulla and recover SO function. The advantage of this device is that it can be rotated clockwise or counterclockwise by turning the handle until the correct position is achieved. Another advantage is if the clip is not in desired position, it may be re-opened and repositioned. Once satisfying clip positioning is achieved, the clip can be firmly attached to the tissue by pulling the slider back until tactile resistance is felt in the handle.

The investigators will recruit patients according to admission criteria and exclusion criteria. The participants underwent SOM before, immediately after EST, and 3 weeks after EST with endoclip papilloplasty. The participants were followed for 3 days during hospitalized. Complications including perforation, bleeding, and PEP were recorded. Blood routine, pancreatic enzymes (amylase and lipase), and liver function (serum alanine aminotransferase, aspartate aminotransferase, r-glutamyl transpeptidase, and alkaline phosphatase) were tested at 4 and 24 h after ERCP. All participants were followed at 3 weeks. Symptoms were examined and blood tests as above were repeated ahead of stents retrieval and sphincter of Oddi monitoring through duodenoscope.
Over one million American adults suffer from cocaine use disorder (CUD) with recent trends showing an increase in cocaine-related deaths since 2010. For the chronic cocaine user, significant changes in brain function and structure set the stage for relapse that, unfortunately, continues to be the most common outcome following treatment. For substance use disorders, cognitive-behavioral therapy (CBT) is arguably the most empirically supported and widely used relapse prevention approach. Considered to be a cognitive control therapy, CBT aims to improve 'top-down' executive control functions that are impaired in CUD and strongly connected to relapse. Converging evidence suggests that CBT promotes meaningful changes in brain regions associated with cognitive control. Still, many patients with cognitive impairments show suboptimal response to CBT, bolstering the call for research aimed at improving effects with integrative treatments.

The goal of this project is to enhance the relapse-prevention effects of CBT with adjunctive use of pioglitazone (PIO), a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist. Unlike traditional medications that target classic neurotransmitter systems, PIO's activation of the PPAR pathway confers broad spectrum anti-inflammatory and neuroprotective effects against insult to brain white matter (WM). The functional significance of WM in CUD has been well established by evidence showing that: (1) chronic cocaine exposure alters WM structural integrity; (2) WM alterations compromise cognitive function in CUD; and (2) better WM integrity predicts better CUD treatment outcome. In a recent proof of concept trial it was found that PIO significantly improved brain WM integrity in a small sample of non-abstinent patients with CUD. Treatment with PIO was well-tolerated and associated with reduced cocaine craving relative to placebo. Collectively, these findings raise the exciting possibility that PIO may augment responding to CBT via improved neural structure and cognitive function.

A randomized double-blind clinical trial will be utilized to evaluate the efficacy of CBT with adjunctive PIO in recently abstinent patients during the early phase of recovery when craving is prominent, relapse risk is high, and intact cognitive control is required to actively maintain abstinence. Upon completion of a 5-day inpatient detoxification, 60 adults with CUD will complete titration to full dose of randomized medication, either PIO (45mg daily) or placebo, and begin 12 weeks of outpatient CBT treatment while continuing to receive study medication. Specific aims will examine the effects of PIO on targeted mechanisms of change (WM integrity, cognitive function, cocaine craving) and demonstrate evidence linking clinical efficacy (abstinence, functional health) with mechanism engagement. Expected results will establish PIO as an adjunctive treatment that can be integrated with CBT to reduce relapse risk following detoxification, thereby meeting NIDA's strategic priority of evaluating the use of medications to improve the efficacy of behavioral interventions (PA-18-055).
The invention relates to a marine streptomyces strain and application thereof. A marine streptomyces sp.HH-1 with the colony induction inhibiting activity is finally obtained by separating an endosymbiosis actinomycetes strain from a marine mollusk body and selecting by a pseudomonas aeruginosa screening model QAIS2 and a purple coli mode strain CV026. The invention, for the first time, proves that the extractive prepared by fermenting the streptomyces strain has double inhibiting functions to the pseudomonas aeruginosa and a purple coli colony induction system and does not restrict the growth of the screening model QAIS2 and the purple coli mode strain CV026 within the effective concentration range. The extractive can remarkably lower the output of the purple coli mycetin and weaken the drug resistance of disease germ. The invention has the advantages that the preparation materials can be easily obtained, the fermentation and cultivation condition of the strain is simple, the technical process for preparing the compound is controllable, the yield is high, and the like. The effective ingredients which are used for inhibiting bacterial colony induction and separated from the marine streptomyces sp.HH-1 ferment extractive can be used for researching and developing novel antibacterial medicines in the medical field.
XERAVA is for intravenous infusion only. Each vial is for a single dose only.

Preparation

XERAVA is supplied as a sterile yellow to orange dry powder in a single-dose vial that must be reconstituted and further diluted prior to intravenous infusion as outlined below. XERAVA does not contain preservatives. Aseptic technique must be used for reconstitution and dilution as follows:

  1. Calculate the dose of XERAVA based on the patient weight; 1 mg/kg actual body weight. Prepare the required dose for intravenous infusion, by reconstituting the appropriate number of vials needed. Reconstitute each vial of XERAVA with 5 mL of Sterile Water for Injection, USP or with 5 mL of 0.9% Sodium Chloride Injection, USP, which will deliver the following: 
    1. XERAVA 50 mg vial will deliver 50 mg (10 mg/mL) of eravacycline (free base equivalents).
  2. XERAVA 100 mg vial will deliver 100 mg (20 mg/mL) of eravacycline (free base equivalents) 
    1. Swirl the vial gently until the powder has dissolved entirely. Avoid shaking or rapid movement as it may cause foaming. The reconstituted XERAVA solution should be a clear, pale yellow to orange solution. Do not use the solution if you notice any particles or the solution is cloudy. Reconstituted solution is not for direct injection. The stability of the solution after reconstitution in the vial has been demonstrated for 1 hour at room temperature (not to exceed 25°C/77°F). If the reconstituted solution in the vial is not diluted in the infusion bag within 1 hour, the reconstituted vial content must be discarded.
  3. The reconstituted XERAVA solution is further diluted for intravenous infusion to a target concentration of 0.3 mg/mL, in a 0.9% Sodium Chloride Injection, USP infusion bag before intravenous infusion. To dilute the reconstituted solution, withdraw the full or partial reconstituted vial content from each vial and add it into the infusion bag to generate an infusion solution with a target concentration of 0.3 mg/mL (within a range of 0.2 to 0.6 mg/mL). Do not shake the bag.
  4. The diluted solutions must be infused within 24 hours if stored at room temperature (not to exceed 25°C/77°F) or within 10 days if stored refrigerated at 2°C to 8°C (36°F to 46°F). Reconstituted XERAVA solutions and diluted XERAVA infusion solutions should not be frozen.
  5. Visually inspect the diluted XERAVA solution for particulate matter and discoloration prior to administration (the XERAVA infusion solution for administration is clear and ranges from light yellow to orange). Discard unused portions of the reconstituted and diluted solution.



Administration of the Intravenous Infusion

The diluted XERAVA solution is administered as an intravenous infusion over approximately 60 minutes.

XERAVA may be administered intravenously through a dedicated line or through a Y-site. If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of XERAVA with 0.9% Sodium Chloride Injection, USP.
BACKGROUND: The Interagency Integrated Triage Tool (IITT) is a three-tier triage instrument recommended by the World Health Organization, but only the pilot version of the tool has been comprehensively assessed for its validity and reliability. This study sought to evaluate the performance of the IITT in a resource-constrained emergency department (ED) during the COVID-19 pandemic.
METHODS: This prospective observational study was conducted at ANGAU Memorial Provincial Hospital in Lae, Papua New Guinea. The study period commenced approximately six weeks after introduction of the IITT, coinciding with a major COVID-19 wave. The primary outcome was sensitivity for the detection of time-critical illness, defined by eight pre-specified conditions. Secondary outcomes included the relationship between triage category and disposition. Inter-rater reliability was assessed using Cohen's Kappa.
RESULTS: There were 759 eligible presentations during the study period. Thirty patients (4.0%) were diagnosed with one of the eight pre-specified time-critical conditions and 21 were categorised as red or yellow, equating to a sensitivity of 70.0% (95%CI 50.6-85.3). There was a clear association between triage category and disposition, with 22 of 53 red patients (41.5%), 72 of 260 yellow patients (27.7%) and 22 of 452 green patients (4.9%) admitted (p = <0.01). Negative predictive values for admission and death were 95.1% (95%CI 92.7-96.9) and 99.3% (95%CI 98.1-99.9) respectively. Among a sample of 106 patients, inter-rater reliability was excellent (κ = 0.83) and the median triage assessment time was 94 seconds [IQR 57-160].
CONCLUSION: In this single-centre study, the IITT's sensitivity for the detection of time-critical illness was comparable to previous evaluations of the tool and within the performance range reported for other triage instruments. There was a clear relationship between triage category and disposition, suggesting the tool can predict ED outcomes. Health service pressures related to COVID-19 may have influenced the findings.
Patients participate in 7 weekly 1-hour group workshops focusing on increasing knowledge and education on the brain and cognition. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3). Patients are then given the option to participate in the memory and thinking skills workshop.
Patients and partners complete questionnaires over 60 minutes about demographic information, stress, coping, and lifestyle behaviors at baseline and end of study. Patients and partners also receive an accelerometer and complete EMA questionnaire on stress, coping, physical activity, and eating behaviors over 5-10 minutes QID (7:30 am, 11:30 am, 3:30 pm, and 7:30 pm) via an smartphone app for 14 days. Patients and partners also complete a survey on nutrition BIW for a total of 4 surveys.
The invention belongs to the technical field of traditional Chinese medicines, and concretely relates to an externally applied traditional Chinese medicinal composition for treating hemorrhoids. The composition is characterized in that the composition is composed of 1-5g of Boswellia carteri, 1-5g of myrrh, 1-5g of Pepperweed Seed, 0.5-2g of cinnabar, 0.5-2g of borax, 1-3g of Chinese Eaglewood, 1-3g of Aplotaxis auriculata, 0.5-2g of realgar, 0.5-2g of borneol and 0.01-0.03g of Venenum Bufonis. The above weights of the above carefully chosen raw materials are ground to fine powder, are disinfected and are packaged to prepare traditional Chinese medicinal composition powder. When the composition is used, 0.01g of the composition is taken, is dissolved in boiled water, and is smeared on the infected part after the infected part is cleaned. The composition is used three times every day, and the amount of the composition can be deliberately increased or decreased according to the disease condition. Clinic verifications prove that the externally applied traditional Chinese medicinal composition has swelling eliminating, sore astringing, slough removing and flesh engendering functions, and has the advantages of substantial curative effect, convenient administration and no side effects.
Hernia recurrences post-repair remain a confounding problem. The prospective study described herein tested Cooper's paradigm, which holds that abdominal pressure exceeding abdominal wall resistance causes hernia, by incorporating the Tensiflex mesh prosthesis which is a modified version of mesh prosthesis of Stoppa technique in the surgical treatment of patients with hernia. The study was 2-phased: the first phase involved the pre-peritoneal implantation of a bi-layered mesh for anatomical replacement of the damaged fascia. The second phase involved the implantation of the bi-layered Tensiflex mesh prosthesis for definitive and seamless augmentation of tensile strength in the myopectineal orifice of Fruchaud.

Eighty-three percent of our patients consumed analgesics for 3 days (3% reported no pain on day 3); however, by day 5, 86% reported pain intensity scores lower than 5. The median number of lost workdays was 7. Most importantly, the primary endpoint of 100% recurrence-free outcomes was met, as were the secondary endpoints (minimal pain, morbidity, and loss of workdays).